{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=34",
    "query": {
      "intervention": "Placebo, Cohort 3",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T02:21:05.110Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06444048",
      "title": "Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Enterovirus Infection"
      ],
      "interventions": [
        {
          "name": "EV68-228-N",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for EV68-228-N",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-06-26",
      "completion_date": "2025-04-11",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06444048"
    },
    {
      "nct_id": "NCT04493931",
      "title": "Drug-drug Interaction Study of Gepotidacin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "Gepotidacin",
          "type": "DRUG"
        },
        {
          "name": "Cimetidine",
          "type": "DRUG"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching to gepotidacin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2020-08-14",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493931"
    },
    {
      "nct_id": "NCT00829816",
      "title": "Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Dimebon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medivation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2008-12",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-10",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 4,
      "location_summary": "Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829816"
    },
    {
      "nct_id": "NCT02655549",
      "title": "A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Px563L, RPA563, or placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfenex, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2015-12",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02655549"
    },
    {
      "nct_id": "NCT01445795",
      "title": "Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "200 mg INX-08189 Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD Fasted",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "Placebo with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-09",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445795"
    },
    {
      "nct_id": "NCT03220295",
      "title": "Putative Cognitive Enhancer VU319",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Single Dose of VU319",
          "type": "DRUG"
        },
        {
          "name": "Single Dose Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fed State",
          "type": "OTHER"
        },
        {
          "name": "Fasted State",
          "type": "OTHER"
        },
        {
          "name": "Dose Escalation of VU319",
          "type": "DRUG"
        },
        {
          "name": "Placebo Dose Escalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2017-07-28",
      "completion_date": "2019-10-30",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220295"
    },
    {
      "nct_id": "NCT03715829",
      "title": "A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Active Non-segmental Vitiligo"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "PF06700841",
          "type": "DRUG"
        },
        {
          "name": "narrow-band UVB phototherapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 366,
      "start_date": "2018-11-26",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 40,
      "location_summary": "Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03715829"
    },
    {
      "nct_id": "NCT02738775",
      "title": "Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 49,
      "start_date": "2016-05-27",
      "completion_date": "2018-08-13",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738775"
    },
    {
      "nct_id": "NCT04220801",
      "title": "A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ZM-H1505R",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Zhimeng Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2020-02-17",
      "completion_date": "2020-11-18",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04220801"
    },
    {
      "nct_id": "NCT02454699",
      "title": "Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "MBX400",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-11-10",
      "completion_date": "2017-12-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-10-18T02:21:05.110Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454699"
    }
  ]
}